ESMO 2012: Tivozanib hydrochloride pharmacokinetic/pharmacodynamic analysis of blood pressure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma
Category: Presentation
ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
ESMO 2012: Pharmacodynamic–pharmacokinetic study of ficlatuzumab, a monoclonal antibody directed to the hepatocyte growth factor (HGF), in patients with advanced solid tumors who have liver metastases
ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma
ESMO 2012: A randomized phase 2 study with exploratory biomarker analysis of ficlatuzumab, a humanized hepatocyte growth factor (HGF) inhibitory monoclonal antibody, in combination with gefitinib versus gefitinib alone in Asian patients with lung adenocarcinoma
ASCO 2012: A Phase II Biomarker Assessment of Tivozanib in ONcology trial in patients (pts) with advanced renal cell carcinoma (BATON RCC)
ASCO 2012: A Phase II Biomarker Assessment of Tivozanib in ONcology trial in patients (pts) with advanced renal cell carcinoma (BATON RCC)
ASCO 2012: Final Results of a Phase Ib Study of Tivozanib and FOLFOX6 in Patients with Advanced Gastrointestinal Tumors
ASCO 2012: Final Results of a Phase Ib Study of Tivozanib and FOLFOX6 in Patients with Advanced Gastrointestinal Tumors
ASCO 2012: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial
ASCO 2012: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR 2012: The Effect of Food on the Pharmacokinetics of Tivozanib
AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib
AACR-NCI-EORTC 2011: A Phase I Study to Evaluate the Absorption, Metabolism and Excretion of the Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Tivozanib
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
AACR-NCI-EORTC 2011: A Phase I QTc Study of Tivozanib in Patients with Advanced Solid Tumors
AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade
AACR-NCI-EORTC 2011: Tivozanib, a selective VEGFR TKI, potently blocks angiogenesis and growth in tumors that express a high level of VEGF-C and are refractory to VEGF-A blockade